Alembic Pharmaceuticals Ltd. NSE: APLLTD | BSE: 533573

Mid-range Performer

Download real time

935.00 -5.05 (-0.54%)

28.29% Fall from 52W High

35,823

NSE+BSE Volume

NSE 24 Sep, 2025 12:41 PM (IST)

Alembic Pharmaceuticals Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Alembic Pharmaceuticals Ltd. from all sources in a single place.

Load latest

Alembic Pharmaceuticals Ltd.

04 Jul 2025

935.00

-0.54%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure …

BSE India

Please find enclosed herewith the Letter sent to Shareholders

Alembic Pharmaceuticals Ltd.

03 Jul 2025

935.00

-0.54%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure …

BSE India

We would like to inform that the Company has received a Demand Note from Office of the Assistant Commissioner of CGST, Gangtok, Sikkim.

Alembic Pharmaceuticals Ltd.

03 Jul 2025

935.00

-0.54%

Alembic Pharma Acquires Utility Therapeutics For $12 Million

NDTV Profit

The acquisition is being done by Alembic Pharmaceuticals, Inc, the company's US subsidiary, Alembic said in a statement.

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals up 2% as arm acquires Utility Therapeutics; details

Business Standard | 03 Jul 2025 1 more

Alembic Pharmaceuticals Ltd.

03 Jul 2025

935.00

-0.54%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure …

BSE India

Alembic Pharmaceuticals Inc. wholly owned subsidiary of Alembic Pharmaceuticals Limited has acquired Utility Therapeutics Ltd.

Alembic Pharmaceuticals Ltd.

02 Jul 2025

935.00

-0.54%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Please find attached herewith a copy of advertisement related to notice of loss of equity share certificate.

Alembic Pharmaceuticals Ltd.

01 Jul 2025

935.00

-0.54%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Volume Movement

BSE India

Please find our response for the volume movement.

Alembic Pharmaceuticals Ltd.

01 Jul 2025

935.00

-0.54%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Clarification sought from Alembic Pharmaceuticals Ltd

BSE India

The Exchange has sought clarification from Alembic Pharmaceuticals Ltd on July 01, 2025, with reference to Movement in Volume. The reply is awaited.

Alembic Pharmaceuticals Ltd.

30 Jun 2025

935.00

-0.54%

Alembic Pharma gets USFDA nod for generic cancer treatment injection

Business Standard

Alembic Pharmaceuticals on Monday said it has received the final approval from the US health regulator for its generic Doxorubicin Hydrochloride Liposome injection in different types of cancer. The approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) is for Doxorubicin Hydrochloride Liposome injection of strengths 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials, Alembic Pharmaceuticals said in a statement. The approved ANDA is therapeutically equivalent to the reference-listed drug product (RLD), Doxil Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL), of Baxter Healthcare Corporation, it added. Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of ovarian Cancer, AIDS-Related Kaposi's sarcoma, and multiple myeloma, the company said. Citing IQVIA data, Alembic said Doxorubicin Hydrochloride Liposome injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2mg/mL) single-dose...

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals gets USFDA nod for generic cancer treatment injection

Business Line | 30 Jun 2025 2 more

Alembic Pharmaceuticals Ltd.

29 Jun 2025

935.00

-0.54%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Alembic Pharmaceuticals Receives USFDA Final Approval For Doxorubicin Hydrochloride Liposome …

BSE India

Please find enclosed the USFDA Approval received for Doxorubicin Hydrochloride Liposome Injection

Alembic Pharmaceuticals Ltd.

26 Jun 2025

935.00

-0.54%

SAST

Alembic Pharmaceuticals Ltd - 533573 - Closure of Trading Window

BSE India

Intimation of Closure of Trading Window

Is Alembic Pharmaceuticals Ltd. worth buying?

239 Votes:

Buy 84.1%

Sell 7.95%

Hold 7.95%

RESEARCH REPORTS

Accumulate SEE REPORTS >

Hold SEE REPORTS >